Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.
about
Pharmacological and non pharmacological strategies in the management of coronary artery disease and chronic kidney diseaseSerum lipoprotein changes in dogs with renal disease.Vitamin E tocotrienol supplementation improves lipid profiles in chronic hemodialysis patients.Racial disparities in kidney disease outcomes.Safety and efficacy of statins in patients with end-stage renal disease.Dyslipidemia in Dialysis Patients.Thromboxane prostanoid receptors enhance contractions, endothelin-1, and oxidative stress in microvessels from mice with chronic kidney disease.Inflammatory stress reduces the effectiveness of statins in the kidney by disrupting HMGCoA reductase feedback regulation.
P2860
Q36021782-D9C6F453-534F-42A7-BACB-02F9918A696DQ36975541-C67B52F8-F775-4B36-A0DC-EA9E456D4770Q37360393-C666F745-10D0-46D2-A63A-6709F5CFE094Q37697378-80A4B6EE-4AF4-4E60-88B1-60D85D10DC8AQ38164683-566E7F4D-70D4-49B9-845F-3BF0CFCBEF1DQ38412228-DCC15FBB-DB0B-44E1-841A-3B83C27156DAQ41667552-53C90C6F-87A9-44D1-BCE1-B6CD1370AD63Q52650772-707FE11D-D09C-4EE5-A07D-9BC33AAFECD2
P2860
Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Reasons for the lack of saluta ...... age renal disease populations.
@en
type
label
Reasons for the lack of saluta ...... age renal disease populations.
@en
prefLabel
Reasons for the lack of saluta ...... age renal disease populations.
@en
P2860
P356
P1433
P1476
Reasons for the lack of saluta ...... age renal disease populations.
@en
P2093
Keith C Norris
Nosratola D Vaziri
P2860
P356
10.1159/000345176
P577
2013-01-22T00:00:00Z